Cargando…
Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension
BACKGROUND: Pancreatic exocrine insufficiency (PEI) often occurs following pancreatic surgery. AIM: To demonstrate the superior efficacy of pancreatin 25 000 minimicrospheres (Creon 25000 MMS; 9–15 capsules/day) over placebo in treating PEI after pancreatic resection. METHODS: A 1-week, double-blind...
Autores principales: | Seiler, C M, Izbicki, J, Varga-Szabó, L, Czakó, L, Fiók, J, Sperti, C, Lerch, M M, Pezzilli, R, Vasileva, G, Pap, Á, Varga, M, Friess, H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601428/ https://www.ncbi.nlm.nih.gov/pubmed/23383603 http://dx.doi.org/10.1111/apt.12236 |
Ejemplares similares
-
Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis - a double-blind, placebo-controlled study
por: Thorat, V, et al.
Publicado: (2012) -
Kreon(®) (Creon(®)) vs. Lipancrea(®): In Vitro Comparison of Two Encapsulated Pancreatin Preparations
por: Hartmann, Sven, et al.
Publicado: (2022) -
Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS
por: Maev, Igor V., et al.
Publicado: (2020) -
Comment on: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Petersen, Karl-Uwe
Publicado: (2021) -
Author’s Reply to Petersen: “Differences in In Vitro Properties of Pancreatin Preparations for Pancreatic Exocrine Insufficiency as Marketed in Russia and CIS”
por: Maev, Igor V., et al.
Publicado: (2021)